Bijan Nejadnik, M.D.: key facts
- Kind of voice
- Sector leader
- Role
- Head of Global Development and Regulatory Affairs, Tanabe Pharma America
- Quoted on
- Rare diseases
- Press citations held
- 1
- Most recently quoted
- 30 Sept 2026
“The limited treatment options for adults with EPP or XLP and lack of any approved treatments for adolescents have created a care deficit, forcing many to endure severe life disruptions as they rely only on sun protection or avoidance.”
Where Bijan Nejadnik, M.D. has been quoted
- Tanabe Pharma's oral drug scores in ph. 3 rare disease study, though details remain in the darkfiercebiotech.com · 30 Sept 2026
Chief executives, directors and spokespeople of trade bodies, representative associations and charities speaking for the sector. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 30 Sept 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.